The share price seems to largely reflect the EPS growth, indicating that investor sentiment towards the shares hasn't changed significantly. The company's consistent positive reception from the market suggests it may be worth watching for potential investment.
IDEXX Laboratories' high P/E ratio, inferior earnings outlook, and slower market growth could lead to a share price decline. This high P/E ratio may not be sustainable, posing a risk to shareholders and potential investors.
爱德士股票讨论区
IDEXX Laboratories Stock In The Last 15 Years!
2023Q1营收增长7.6%,营业利润增长12.9%,净利润增长10.4%。
目前市盈率68,市盈率TTM略降到65.8,和增速比估值过高,缺乏投资价值。
暂无评论